|| Checking for direct PDF access through Ovid
Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis in infants. Palivizumab is an anti-RSV monoclonal antibody providing passive immunity against RSV. The Joint Committee for Vaccination and Immunisation (JCVI) have produced guidelines for high-risk babies that fulfil the criteria for receiving Palivizumab.Service evaluation of the dedicated Paviluzumab clinic with flexible appointment times.Babies eligible for Paviluzumab were selected using the Badger electronic database and the JCVI criteria. We carried out a service evaluation of the clinics over the winter months 2012/2013. A parent satisfaction questionnaire was collected on the final clinic appointment.13 babies attended the clinics and all met the JCVI criteria. The mean gestational age was 26+4 weeks (range 23+6 to 31+4). The average number of days spent on oxygen was 55 days. 31% were discharged home on oxygen. Attendance at the clinics was excellent with only 1 baby who missed the last clinic due to a hospital admission. 62% of the babies had an inpatient stay in hospital during the RSV season but there were no confirmed cases of RSV. 12 out of 13 parents responded to our questionnaire. 100% of parents were ‘very satisfied’ with the overall care. No questions were responded to with ‘very unsatisfied’. Parents were least satisfied with their ability to recognise the symptoms of bronchiolitis.More information should be given to the parents to help them recognise the signs and symptoms of bronchiolitis. Flexible appointment times are an important factor in ensuring good attendance.